Caris Life Sciences, Inc. Common Stock (CAI)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $8.0B, Caris Life Sciences, Inc. Common Stock's free cash flow of $67M (fiscal 2025) would need to grow about 29% a year for the stock to be worth today's price.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Caris Life Sciences, Inc. Common Stock's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from CAI's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Caris Life Sciences, Inc. Common Stock's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $306M | $412M | $812M |
| Net income | -$341M | -$282M | -$68M |
| Free cash flow | -$298M | -$254M | $67M |
| EPS (diluted) | -$13.24 | -$10.66 | -$3.22 |
| Operating margin | -104.4% | -62.4% | 5.6% |
Where the revenue comes from
Revenue by products, fiscal 2025.
Superinvestors who own CAI
From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Philippe Laffont Coatue Management |
Held | $175M | 0.36% | Q2 2026 |
| Stanley Druckenmiller Duquesne Family Office |
Held | $34M | 0.65% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Added | $28M | 0.02% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $2M | 0.00% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $1M | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by Caris Life Sciences, Inc. Common Stock's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when CAI trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
What growth does Caris Life Sciences, Inc. Common Stock's stock price imply?
At a market value of $8.0B, Caris Life Sciences, Inc. Common Stock would need its free cash flow to grow about 29% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price.
Are Caris Life Sciences, Inc. Common Stock insiders buying the stock?
No open-market insider purchases of CAI in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Caris Life Sciences, Inc. Common Stock?
5 of the superinvestors Investingly tracks hold CAI in their latest 13F, including Philippe Laffont, Stanley Druckenmiller, Hersh Cohen.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.